Hsbc Holdings PLC Makes New Investment in Vaxcyte, Inc. (NASDAQ:PCVX)

Hsbc Holdings PLC acquired a new stake in Vaxcyte, Inc. (NASDAQ:PCVX) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 13,946 shares of the company’s stock, valued at approximately $1,053,000.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its stake in Vaxcyte by 15.2% in the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock valued at $665,152,000 after buying an additional 1,284,883 shares during the last quarter. RA Capital Management L.P. increased its position in shares of Vaxcyte by 4.0% in the first quarter. RA Capital Management L.P. now owns 8,203,754 shares of the company’s stock valued at $560,398,000 after acquiring an additional 312,500 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Vaxcyte by 9.9% in the first quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock valued at $524,117,000 after acquiring an additional 692,492 shares during the last quarter. Capital Research Global Investors raised its holdings in Vaxcyte by 20.4% during the first quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock worth $282,839,000 after acquiring an additional 700,414 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in Vaxcyte by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company’s stock valued at $216,966,000 after purchasing an additional 498,359 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

Analyst Ratings Changes

PCVX has been the topic of a number of analyst reports. Needham & Company LLC upped their price objective on Vaxcyte from $95.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Leerink Partners increased their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research note on Tuesday, September 3rd. BTIG Research boosted their price objective on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Bank of America upped their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Finally, Jefferies Financial Group lifted their price target on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte presently has a consensus rating of “Buy” and an average target price of $147.50.

Insider Buying and Selling

In other Vaxcyte news, SVP Mikhail Eydelman sold 1,667 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $76.37, for a total transaction of $127,308.79. Following the transaction, the senior vice president now owns 30,826 shares in the company, valued at approximately $2,354,181.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Vaxcyte news, CEO Grant Pickering sold 2,616 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $76.33, for a total transaction of $199,679.28. Following the transaction, the chief executive officer now owns 143,438 shares in the company, valued at approximately $10,948,622.54. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Mikhail Eydelman sold 1,667 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $76.37, for a total transaction of $127,308.79. Following the transaction, the senior vice president now directly owns 30,826 shares in the company, valued at $2,354,181.62. The disclosure for this sale can be found here. In the last ninety days, insiders sold 78,283 shares of company stock valued at $7,064,138. Insiders own 3.10% of the company’s stock.

Vaxcyte Price Performance

Shares of PCVX opened at $113.14 on Friday. The company’s 50-day moving average is $92.24 and its 200-day moving average is $77.84. The firm has a market capitalization of $12.63 billion, a PE ratio of -26.43 and a beta of 0.97. Vaxcyte, Inc. has a fifty-two week low of $44.20 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.04. During the same quarter in the prior year, the firm earned ($0.70) earnings per share. Analysts predict that Vaxcyte, Inc. will post -4.33 earnings per share for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.